Advanced

Smoking is the most significant modifiable lung cancer risk factor in systemic lupus erythematosus

Bernatsky, Sasha; Ramsey-Goldman, Rosalind; Petri, Michelle; Urowitz, Murray B.; Gladman, Dafna D.; Fortin, Paul R.; Yelin, Edward H.; Ginzler, Ellen; Hanly, John G. and Peschken, Christine, et al. (2018) In Journal of Rheumatology 45(3). p.393-396
Abstract

Objective. To assess lung cancer risk in systemic lupus erythematosus (SLE), relative to demographics, drug exposures, smoking, and disease activity. Methods.We analyzed data from 14 SLE cohorts. We calculated adjusted HR estimates for lung cancer in SLE, relative to demographics, smoking, time-dependent medication exposures, and cumulative disease activity [mean adjusted SLE Disease Activity Index (SLEDAI) scores]. This project was approved by the ethics boards of all participating institutions, including the Institutional Review Board of the McGill University Health Centre. The ethics approval number for the Cancer Risk study is GEN-06-031. Results. Within these 14 SLE cohorts, 49 incident lung cancers occurred. Among lung cancer... (More)

Objective. To assess lung cancer risk in systemic lupus erythematosus (SLE), relative to demographics, drug exposures, smoking, and disease activity. Methods.We analyzed data from 14 SLE cohorts. We calculated adjusted HR estimates for lung cancer in SLE, relative to demographics, smoking, time-dependent medication exposures, and cumulative disease activity [mean adjusted SLE Disease Activity Index (SLEDAI) scores]. This project was approved by the ethics boards of all participating institutions, including the Institutional Review Board of the McGill University Health Centre. The ethics approval number for the Cancer Risk study is GEN-06-031. Results. Within these 14 SLE cohorts, 49 incident lung cancers occurred. Among lung cancer cases, 59.0% were in the highest SLEDAI quartile at baseline versus 40.8% of lung cancer-free SLE controls. The vast majority (84.2%) of SLE lung cancer cases were ever-smokers at baseline, versus 40.1% of those without lung cancer. In adjusted models, the principal factors associated with lung cancer were ever smoking (at cohort entry) and current age. Estimated adjusted effects of all drugs were relatively imprecise, but did not point toward any drug exposures as strong lung cancer risk factors. Conclusion. We saw no clear evidence for drugs as a trigger for lung cancer risk in SLE, although drug risk estimates were relatively imprecise. Smoking may be the most significant modifiable lung cancer risk factor in SLE.

(Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Lung cancer, Systemic lupus erythematosus
in
Journal of Rheumatology
volume
45
issue
3
pages
4 pages
publisher
J Rheumatol Publ Co
external identifiers
  • scopus:85042724497
ISSN
0315-162X
DOI
10.3899/jrheum.170652
language
English
LU publication?
no
id
cc9b0cac-3934-4ab6-bff1-6f4174b4dfaa
date added to LUP
2018-04-12 12:58:21
date last changed
2019-07-16 03:47:42
@article{cc9b0cac-3934-4ab6-bff1-6f4174b4dfaa,
  abstract     = {<p>Objective. To assess lung cancer risk in systemic lupus erythematosus (SLE), relative to demographics, drug exposures, smoking, and disease activity. Methods.We analyzed data from 14 SLE cohorts. We calculated adjusted HR estimates for lung cancer in SLE, relative to demographics, smoking, time-dependent medication exposures, and cumulative disease activity [mean adjusted SLE Disease Activity Index (SLEDAI) scores]. This project was approved by the ethics boards of all participating institutions, including the Institutional Review Board of the McGill University Health Centre. The ethics approval number for the Cancer Risk study is GEN-06-031. Results. Within these 14 SLE cohorts, 49 incident lung cancers occurred. Among lung cancer cases, 59.0% were in the highest SLEDAI quartile at baseline versus 40.8% of lung cancer-free SLE controls. The vast majority (84.2%) of SLE lung cancer cases were ever-smokers at baseline, versus 40.1% of those without lung cancer. In adjusted models, the principal factors associated with lung cancer were ever smoking (at cohort entry) and current age. Estimated adjusted effects of all drugs were relatively imprecise, but did not point toward any drug exposures as strong lung cancer risk factors. Conclusion. We saw no clear evidence for drugs as a trigger for lung cancer risk in SLE, although drug risk estimates were relatively imprecise. Smoking may be the most significant modifiable lung cancer risk factor in SLE.</p>},
  author       = {Bernatsky, Sasha and Ramsey-Goldman, Rosalind and Petri, Michelle and Urowitz, Murray B. and Gladman, Dafna D. and Fortin, Paul R. and Yelin, Edward H. and Ginzler, Ellen and Hanly, John G. and Peschken, Christine and Gordon, Caroline and Nived, Ola and Aranow, Cynthia and Bae, Sang Cheol and Isenberg, David and Rahman, Anisur and Hansen, James E. and Pierre, Yvan St and Clarke, Ann E.},
  issn         = {0315-162X},
  keyword      = {Lung cancer,Systemic lupus erythematosus},
  language     = {eng},
  month        = {03},
  number       = {3},
  pages        = {393--396},
  publisher    = {J Rheumatol Publ Co},
  series       = {Journal of Rheumatology},
  title        = {Smoking is the most significant modifiable lung cancer risk factor in systemic lupus erythematosus},
  url          = {http://dx.doi.org/10.3899/jrheum.170652},
  volume       = {45},
  year         = {2018},
}